nach oben

Erschienen in:

18.06.2020 | Review Article

A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life

verfasst von: L. M. Wiltink, M. King, F. Müller, M. S. Sousa, M. Tang, A. Pendlebury, J. Pittman, N. Roberts, L. Mileshkin, R. Mercieca-Bebber, M.-A. Tait, R. Campbell, C. Rutherford

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Given the high survival rate of cervical cancer patients, understanding women’s health-related quality of life (HRQL) during and after treatment is of major clinical importance. We conducted a systematic review to synthesize all available evidence about the effects of each contemporary treatment modality for cervical cancer on all dimensions of women’s HRQL, including symptoms, functioning, and global HRQL.

Methods

We searched four electronic databases from January 2000 to September 2019, cross-referenced and searched by author name for studies of patients treated for cervical cancer that reported patient-reported outcomes (PROs) before treatment and with at least one post-treatment measurement. Two independent reviewers applied inclusion and quality criteria and extracted findings. Studies were categorized by treatment to determine specific treatment effects on PROs. Results were narratively summarized.

Results

We found twenty-nine papers reporting 23 studies. After treatments with curative intent for early or locally advanced disease, lymphedema, diarrhea, menopausal symptoms, tight and shorter vagina, pain during intercourse, and sexual worries remained long-term problems; however, sexual activity improved over time. HRQL and psychological distress were impacted during treatment with also worsening of global HRQL but improved 3–6 months after treatment. In patients with metastatic or recurrent disease, pain improved during palliative treatment or remained stable, with no differences in global HRQL found over time.

Conclusion

Whereas most symptoms worsen during treatment and improve in the first 3 months after completing treatment, symptoms like lymphedema, menopausal symptoms, and sexual worries develop gradually and persist after curative treatment. These findings can be used to inform clinical practice and facilitate communication and shared decision-making. More research is needed in very early cervical cancer and the impact of fertility sparing therapy on PROs.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef

Noone AM, H N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2018) SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site

Marth C et al (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 28(suppl_4):iv72–iv83PubMed

Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet 393(10167):169–182PubMed

Bhatla N et al (2018) Cancer of the cervix uteri. Int J Gynaecol Obstet 143(Suppl 2):22–36PubMed

Bhatla N et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135PubMed

Shimamoto K, Saito T, Kitade S, Tomita Y, Nagayama R, Yamaguchi S, Ariyoshi K, Okadome M (2018) A study of treatments and outcomes in elderly women with cervical cancer. Eur J Obstet Gynecol Reprod Biol 228:174–179PubMed

Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12(3):608–616PubMed

Rutherford C, M-B R., Tait M, Mileshkin L, King M (2017) Quality of life in cervical cancer. In: Farghaly S (editor) Uterine cervical cancer: clinical and therapeautic perspectives. Springer, New York. https://doi.org/10.1007/978-3-030-02701-8 [ISBN (Print): 978-3-030-02700-1; ISBN (EBook): 978-3-030-02700-1]

10.

Food and Drug Administration (2009) Patient reported outcome measures: use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration

11.

Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)

12.

Kmet LM, Lee RC, Cook LS (2004) Standard quality assessment criteria for evaluating primary research papers froma variety of fields. Alberta Heritage Foundation for Medical Research, Edmonton

13.

Calvert MP et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822PubMed

14.

Bogani G, Serati M, Nappi R, Cromi A, di Naro E, Ghezzi F (2014) Nerve-sparing approach reduces sexual dysfunction in patients undergoing laparoscopic radical hysterectomy. J Sex Med 11(12):3012–3020PubMed

15.

Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR (2010) A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol 119(2):358–365PubMedPubMedCentral

16.

Conic I et al (2012) Anxiety levels related to the type of therapy for cervical cancer. Central Eur J Med 7(4):490–496

17.

Ding Y, Hu Y, Hallberg IR (2013) Health-related quality of life and associated factors in Chinese women with cervical cancer: a 9-month follow-up. Cancer Nurs 36(4):E18–E26PubMed

18.

Du Toit GC, Kidd M (2015) Prospective quality of life study of south African women undergoing treatment for advanced-stage cervical cancer. Clin Ther 37(10):2324–2331PubMed

19.

Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Moruzzi C, Lorusso D, Marcellusi A, Scambia G (2012) Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol 124(3):389–394PubMed

20.

Hawighorst-Knapstein S, Fusshoeller C, Franz C, Trautmann K, Schmidt M, Pilch H, Schoenefuss G, Georg Knapstein P, Koelbl H, Kelleher DK, Vaupel P (2004) The impact of treatment for genital cancer on quality of life and body image - results of a prospective longitudinal 10-year study. Gynecol Oncol 94(2):398–403PubMed

21.

Heijkoop ST, Nout RA, Quint S, Mens JWM, Heijmen BJM, Hoogeman MS (2017) Dynamics of patient reported quality of life and symptoms in the acute phase of online adaptive external beam radiation therapy for locally advanced cervical cancer. Gynecol Oncol 147(2):439–449PubMed

22.

Jiang H et al (2016) Vaginal extension improves sexual function in patients receiving laparoscopic radical hysterectomy. Gynecol Oncol 27

23.

Liu B, Li L, Wang M, Wei L, Li J, Zou W, Lv Y, Zhang H, Liu S (2019) Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: a single-institutional retrospective study from a prospective database. Gynecol Oncol 154(3):583–589PubMed

24.

Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Anchora LP, Scambia G, Ferrandina G (2013) Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. BMC Cancer 13:127PubMedPubMedCentral

25.

Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JBMZ, ter Kuile MM (2013) Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. Int J Gynecol Cancer 23(9):1717–1725PubMed

26.

He H et al (2017) Laparoscopic radical surgery in early-stage cervical cancer: short-term and long-term outcomes and survival analysis. Int J Clin Exp Med 10(8):12044–12055

27.

Barnas E et al (2012) The quality of life of women treated for cervical cancer. Eur J Oncol Nurs 16(1):59–63PubMed

28.

Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M (2016) Quality of life after radical trachelectomy for early-stage cervical cancer: a 5-year prospective evaluation. Gynecol Oncol 143(3):596–603PubMedPubMedCentral

29.

Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K (2018) Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol 127(3):423–430PubMed

30.

Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K, EMBRACE Collaborative Group (2018) Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol 127(3):431–439PubMed

31.

Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267PubMed

32.

Kirchheiner K, Nout RA, Czajka-Pepl A, Ponocny-Seliger E, Sturdza AE, Dimopoulos JC, Dörr W, Pötter R (2015) Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol 136(3):415–423PubMed

33.

Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA, Lindegaard J, Tanderup K, Fokdal L, van der Steen Banasik E, Haie-Meder C, Dumas I, Chargari C, Nout RA, van Limbergen E, Petrič P, Segedin B, Hudej R, Erickson B, Hoskin P, Lowe G, Mahantshetty U, Swamidas J, Shrivastava SK, Jürgenliemk-Schulz IM, de Leeuw A, Kirchheiner K, Dörr W, Pötter R, Lutgens LCHW, Hadjiev J, Cooper R, Bownes P, Sundset M, Bruheim K, Hellebust TP, Huang F, Menon G, Villafranca E, Rai B, Oinam AS, Tan LT, Bachand F, Jacobson G, Anttila M, Pieters B (2016) Health-related quality of life in locally advanced cervical cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys 94(5):1088–1098PubMed

34.

Ljuca D, Marosevic G (2011) Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer. Bosnian J Basic Med Sci 11(1):62–64

35.

Najjari Jamal D, Pötter R, Haie-Meder C, Lindegaard JC, Juergenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Tanderup K, Kirchheiner K, EMBRACE collaborative group (2018) Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: a report from the EMBRACE study. Radiother Oncol 127(3):449–455PubMed

36.

Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van Limbergen E, Tanderup K, Kirchheiner K, EMBRACE Collaborative Group (2018) Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Radiother Oncol 127(3):440–448PubMed

37.

Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedPubMedCentral

38.

Long IHJ et al (2006) Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 100(3):537–543PubMed

39.

McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 101(2):296–304PubMed

40.

Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 23(21):4617–4625

41.

Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15):3113–3119PubMed

42.

Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ III, Ramondetta LM, Landrum LM, Oaknin A, Reid TJA, Leitao MM, Method M, Michael H, Tewari KS (2015) Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 16(3):301–311PubMedPubMedCentral

43.

Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713–1721PubMed

44.

Kim JH, Park EC (2015) Impact of socioeconomic status and subjective social class on overall and health-related quality of life. BMC Public Health 15:783PubMedPubMedCentral

45.

van Gent MD et al (2016) Nerve-sparing radical hysterectomy versus conventional radical hysterectomy in early-stage cervical cancer. A systematic review and meta-analysis of survival and quality of life. Maturitas 94:30–38PubMed

46.

Xue Z, Zhu X, Teng Y (2016) Comparison of nerve-sparing radical hysterectomy and radical hysterectomy: a systematic review and meta-analysis. Cell Physiol Biochem 38(5):1841–1850PubMed

47.

Gubbala K, Laios A, Gallos I, Pathiraja P, Haldar K, Ind T (2014) Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. J Ovarian Res 7(1):69PubMedPubMedCentral

48.

Vistad I, Fossa SD, Dahl AA (2006) A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 102(3):563–572PubMed

49.

Pfaendler KS, Wenzel L, Mechanic MB, Penner KR (2015) Cervical cancer survivorship: long-term quality of life and social support. Clin Ther 37(1):39–48PubMedPubMedCentral

50.

Klugel S et al (2017) Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review. Int J Women's Health 9:795–805

51.

Ye S, Yang J, Cao D, Lang J, Shen K (2014) A systematic review of quality of life and sexual function of patients with cervical cancer after treatment. Int J Gynecol Cancer 24(7):1146–1157PubMed

52.

Lammerink E et al (2012) Sexual functioning of cervical cancer survivors: a review with a female perspective. Int J Gynecol Cancer 22:E649

Titel: A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life
verfasst von: L. M. Wiltink
M. King
F. Müller
M. S. Sousa
M. Tang
A. Pendlebury
J. Pittman
N. Roberts
L. Mileshkin
R. Mercieca-Bebber
M.-A. Tait
R. Campbell
C. Rutherford
Publikationsdatum: 18.06.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05554-2

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life